1. Didanosine-induced Retinopathy: New Insights with Long-term Follow-up
- Author
-
Isabelle Audo, Céline Faure, Maxime Chassery, and Raphaelle Ores
- Subjects
medicine.medical_specialty ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Ophthalmology ,medicine ,Immunology and Allergy ,Didanosine ,Retinal pigment epithelium ,medicine.diagnostic_test ,business.industry ,Retinal ,medicine.disease ,Photoreceptor outer segment ,Pathophysiology ,3. Good health ,Discontinuation ,medicine.anatomical_structure ,chemistry ,030221 ophthalmology & optometry ,business ,030217 neurology & neurosurgery ,Electroretinography ,medicine.drug ,Retinopathy - Abstract
Introduction: Didanosine is an adenosine analog, part of the nucleoside reverse-transcriptase inhibitor family. Since the description of didanosine-induced retinopathy in the early 1990s, little is known about the progression of this toxic retinopathy and the putative underlying mitochondrial defect.Objectives: We report long-term follow-up for cases of didanosine-induced retinopathy and discuss a new hypothesis for pathophysiology based on the alteration of endogenous adenosine on the photoreceptor outer segment turnover and phagocytosis by the retinal pigment epithelium.Methods: Ophthalmic data from six cases (12 eyes) of didanosine-induced retinopathy from a single institution were retrospectively analyzed.Results: All patients displayed bilateral retinal alterations in the mid-periphery. Despite didanosine discontinuation, patients with advanced areas of patchy chorioretinal atrophy appeared to have a faster progression than those with limited lesions. Full-field electroretinogram revealed generalized rod-cone dysfunction in most cases that remained stable over time.Conclusion: We propose new guidelines including early screening and long-term observations.
- Published
- 2021
- Full Text
- View/download PDF